Ang Israeli C0VID drug na kini-claim nilang may 100% success rate sa mga severely ill na pasyente ay ginamit upang e test sa United States sa unang pagkakataon.
The trial comes after Pluristem Therapeutics Inc., a biotech company na naka base sa Haifa,ibinalita noong nakaraang linggo na may pitong pasyente na mataas ang posibilidad na mamamatay dahil sa respiratory failure ay naka SURVIVE pagkatapos makatanggap nitong gamot.
The patients were approved for treatment under the compassionate use program and exhibited respiratory failure requiring intubation in the ICU. Four of the patients had multi-system organ failure, including heart and kidney failure.
Ang pitong pasyente ay ginamot gamit ang Pluristem’s allogeneic placental expanded (PLX) cells. Essentially, these cells can potentially suppress or reverse the dangerous over-activation of the immune system that causes death in many coronavirus patients.
Pluristem uses “donated placentas at the time of delivery of healthy, full-term babies, from healthy women under 35 years old, undergoing an elective caesarean section,” a spokesperson told CBN News.
All seven of the patients who received the drug survived and four patients saw an improvement in respiration. One patient is still alive but saw a continued deterioration of their respiratory system.
Sa ngayon, ang isang Critical C0VID-19 na pasyente sa US ay ginagamot gamit ang PLX cell therapy sa Holy Name Medical Center sa New Jersey. Ang resulta ng nasabing gamutan ay ipalalabas pa lamang.
Pluristem aims to conduct a multinational clinical study on the drug to better test for its effectiveness.
“We are pleased with this initial outcome of the compassionate use program, and committed to harnessing PLX cells for the benefit of patients and healthcare systems. In order to maximize PLX cells’ impact on patient recovery and to work towards making our treatment widely available, we plan to quickly move forward into a clinical development program,” stated Pluristem CEO and President, Yaky Yanay.
SOURCE: CBN NEWS